MAPT and Alzheimer disease: To achieve this aim, we explored whether AD biomarkers (i.e., Aβ42 and Tau) may affect the odds of SCD, combining data from two ongoing studies: the Hellenic Longitudinal Investigation of Aging and Diet (HELIAD) and the Aiginition Longitudinal Biomarker Investigation of Neurodegeneration (ALBION).